AWARDDEFINITIVE CONTRACTOther than small business
Definitive contract 75F40125C00095DNA HIVE LLC
Overview
Award facts
- Net obligations
- $7.46M
- $7,461,715of $7.46M potential value
- Outlays (paid to date)
- $807.2K
- $807.2K paid of $7.46M obligated$807,202
- Period of performance
- Sep 23, 2025 to Sep 29, 2028
- Ends in 22 months
- Modifications
- 1
- Latest action Sep 24, 2026
- Contract type
- Definitive contract
- PIID 75F40125C00095
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
BAA# FY25C3AP3 - (H20) A NEXT GENERATION MEDICAL COUNTERMEASURES SCIENTIFIC PLATFORM FOR REGULATORY EVALUATION AND PREPAREDNESS
Dates and value
- Award date
- Signed on Sep 23, 2025
- Current value
- $7,461,715Base and exercised options
- Potential value (if all options are exercised)
- $7,461,715
Obligations by fiscal year of action
- FY2026: $4,371,000
- FY2025: $3,090,715
Total across 2 fiscal years: $7,461,715
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Sep 24, 2026. View on USAspending · Recipient on SAM.gov
Recipient
NameDNA HIVE LLC
LocationROCKVILLE, MD
UEIZULRXE8XYEM3
CAGE code8B9Q6
Business sizeOther than small businessSize at award, per the contracting officer
Organization typePartnership
Parent companyDNA HIVE LLC
Business types and certifications
Women-ownedWomen-owned small business (WOSB)Self-certified small disadvantaged businessFor-profit organizationLimited liability companyPartnership or LLP
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded by
- Department of Health and Human Services
- Food And Drug Administration
- FDA OFFICE OF ACQ GRANT SVCS
- Funded from
- General departmental management; Fda other activities (fda headquaters)Program activities075-0120, 075-0600Federal accounts (agency financial reports)
Place of performance
- Place of performance
- Rockville, Montgomery County, Maryland 20853-1104
- Congressional district (place of performance)
- MD-08As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN11HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH (research and development)
Competition
- Extent competed
- Full and open competitionA
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- No set-aside used
- Contract pricing
- Cost no feeS
- Offers received
- 1
Solicitation and notices
- Solicitation ID
- FDABAA-25-00123
- Solicitation date
- Jun 4, 2025
- Notices
- Special Notice posted Feb 26, 2025
- Special Notice posted Feb 26, 2025
- Special Notice posted Feb 24, 2025
- Special Notice posted Feb 24, 2025
- Special Notice posted Dec 6, 2024
- Special Notice posted Nov 19, 2024
- Special Notice posted Nov 15, 2024
- Special Notice posted Oct 3, 2024
- Special Notice posted Oct 3, 2024
Contract details
- Subcontracting plan
- Plan not requiredB
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Service Contract Act labor standards
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Sep 23, 2025Base obligation at award: $3,090,715
- Latest action
- Sep 24, 2026 — Supplemental agreement (within scope)Modification P00001; obligation change +$4,371,000
- Latest substantive action
- Sep 24, 2026 — Supplemental agreement (within scope)Modification P00001; obligation change +$4,371,000
- Actions by type
- Base award1
- Supplemental agreement (within scope)1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
Pricing and financing
- Paid by purchase card
- No
- Latest action: change in base and exercised options
- $4,371,000
- Latest action: change in base and all options
- $4,371,000
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Walsh-Healey Act (materials and supplies)
- No
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7524
- Contracting office code
- 75F401
- Transactions recorded under this award key
- 2
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7524
- Funding office code
- 75F401
- Treasury accounts
- 075-2025/2025-0120-000
- 075-2025/2025-0600-000
- Object classes
- 25.5: Research and development contracts
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression